Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial

Ubrogepant is a novel, oral calcitonin gene–related peptide receptor antagonist currently under US Food and Drug Administration (FDA) review for the acute treatment of migraine attacks. This double‐blind, four‐period crossover study compared the cardiac repolarization effect of therapeutic (100 mg)...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakate, Abhijeet, Boinpally, Ramesh, Butler, Matthew, Lu, Kaifeng, McGeeney, Danielle, Periclou, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158215/
https://www.ncbi.nlm.nih.gov/pubmed/31628854
http://dx.doi.org/10.1002/cpt.1696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158215/
https://www.ncbi.nlm.nih.gov/pubmed/31628854
http://dx.doi.org/10.1002/cpt.1696

Ejemplares similares